New Leaf Brands (NLB.C) subsidiary Mydecine’s new facility aims to unlock the potential in psilocybin mushrooms
A randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and… Read More »New Leaf Brands (NLB.C) subsidiary Mydecine’s new facility aims to unlock the potential in psilocybin mushrooms





